- Home
- ABOS
as 07-26-2024 4:00pm EST
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CHARLOTTESVILLE |
| Market Cap: | 204.3M | IPO Year: | 2021 |
| Target Price: | $10.75 | AVG Volume (30 days): | 673.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $7.62 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| OConnell Daniel Joseph | ABOS | President and CEO | Jan 19 '24 | Sell | $3.47 | 15,200 | $52,753.12 | 502,485 | SEC Form 4 |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 19 '24 | Sell | $3.48 | 8,933 | $31,048.43 | 108,867 | SEC Form 4 |
| Barton Russell | ABOS | Chief Operating Officer | Jan 18 '24 | Sell | $3.73 | 2,833 | $10,555.19 | 96,867 | SEC Form 4 |
| Siemers Eric | ABOS | Chief Medical Officer | Jan 18 '24 | Sell | $3.71 | 3,124 | $11,603.79 | 117,576 | SEC Form 4 |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 18 '24 | Sell | $3.71 | 4,242 | $15,716.61 | 211,445 | SEC Form 4 |
Latest Acumen Pharmaceuticals Inc. News
ABOS Breaking Stock News: Dive into ABOS Ticker-Specific Updates for Smart Investing
MT Newswires
17 hours ago
Citigroup Starts Acumen Pharmaceuticals With Buy Rating, $7 Price Target
GlobeNewswire
16 days ago
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Insider Monkey
a month ago
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?
GuruFocus.com
2 months ago
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Thomson Reuters StreetEvents
2 months ago
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
GlobeNewswire
2 months ago
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
2 months ago
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
MT Newswires
2 months ago
Arthur J. Gallagher Acquires Acumen Advisors
Compare ABOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.